Press release - 08/02/2022 New European Research Council grant for Max Plack Researcher The European Research Council is funding a large-scale proof-of-concept study on a new genome sequencing method called “Haplotagging”. Haplotagging is a new method for sequencing our genome with superior quality and faster speed, developed by group leader Frank Chan and his team at the Friedrich Miescher Laboratory at the Max Planck Campus, Tübingen, Germany.https://biopro-v9-test-gi.xanium.io/en/article/press-release/new-european-research-council-grant-max-plack-researcher
Press release - 03/02/2022 The 5G-OR Project is a Winner of the joint Franco-German Program for the Development of innovative Applications for 5G private Networks 5G-OR is one of the 4 winning projects jointly selected by the Federal Ministry of Economics and Climate Action in Germany and the Ministry of Economy, Finance and Relaunch in France for the call “Technical developments and application ecosystems for 5G private networks”. The joint Franco-German 5G-OR project takes up the challenge in the healthcare domain.https://biopro-v9-test-gi.xanium.io/en/article/press-release/5g-or-project-winner-joint-franco-german-program-development-innovative-applications-5g-private-networks
Press release - 20/12/2021 Immune microenvironment as a risk factor for colorectal cancer in Lynch syndrome Researchers at Heidelberg University Hospital (UKHD), the German Cancer Research Center (DKFZ) and at the National Center for Tumor Diseases (NCT) Heidelberg have demonstrated for the first time that there is a link between the development of colorectal cancer in individuals with Lynch syndrome and the composition of immune cells in the colorectal mucosa.https://biopro-v9-test-gi.xanium.io/en/article/press-release/immune-microenvironment-risk-factor-colorectal-cancer-lynch-syndrome
Press release - 14/12/2021 EU regulation approved: G-BA collaborates on European health technology assessment Today, the EU Parliament adopted the EU Regulation on Health Technology Assessment (HTA), which includes not only new medicines (including gene and cell therapies), but also medical devices.https://biopro-v9-test-gi.xanium.io/en/article/press-release/eu-regulation-approved-g-ba-collaborates-european-health-technology-assessment
Press release - 29/11/2021 Tracking down resistant cancer cells In multiple myeloma, a cancer of the bone marrow, relapse almost always occurs after treatment. Initially, most patients respond well to therapy. However, as the disease progresses, resistant cancer cells spread in the bone marrow, with fatal consequences for the patients.https://biopro-v9-test-gi.xanium.io/en/article/press-release/tracking-down-resistant-cancer-cells
Funding Digital Europe Programme Funding programme, Funded by: European Commission, sb_search.searchresult.label.programSubmissionDate: 31/12/2027 https://biopro-v9-test-gi.xanium.io/en/database/funding/digital-europe-programme
Press release - 18/11/2021 Overcoming resistance to treatment for breast, bowel, and pancreatic cancer As cancer progresses, the tumor cells continually change, ultimately resulting in a tumor consisting of a large number of different cell clones with different characteristics. This is referred to as "tumor heterogeneity". In many cases, the cancer cells become resistant to the treatments available.https://biopro-v9-test-gi.xanium.io/en/article/press-release/overcoming-resistance-treatment-breast-bowel-and-pancreatic-cancer
Press release - 18/11/2021 Overcoming resistance to cancer treatment: bone and soft tissue tumors in adolescents as a model system Treatment resistance is a central problem in the treatment of cancer. Bone and soft tissue tumors – known as sarcomas – in adolescents and young adults often stop responding to treatment too. This is because cancer cells develop a large number of new characteristics as the disease progresses and often become resistant to drugs that were originally effective.https://biopro-v9-test-gi.xanium.io/en/article/press-release/overcoming-resistance-cancer-treatment-bone-and-soft-tissue-tumors-adolescents-model-system
Funding EU4Health- Programme Funding programme, Funded by: European Union, sb_search.searchresult.label.programSubmissionDate: 31/12/2027 https://biopro-v9-test-gi.xanium.io/en/database/funding/eu4health-programme
Press release - 20/08/2021 Innovative Drug Discovery New drugs are intended to help stop viral zoonoses – infections that jump from animals to humans. To study suitable inhibitors, Prof. Dr Christian Klein from the Institute of Pharmacy and Molecular Biotechnology (IPMB) of Heidelberg University is receiving funding in the amount of 450,000 euros from the Volkswagen Foundation. https://biopro-v9-test-gi.xanium.io/en/article/press-release/innovative-drug-discovery
Press release - 13/08/2021 Paradigm shift in immunology 'Adaptive Tolerance' balances autoimmune reaction Immunologists at Ulm University and its Medical Centre have developed a new model that could revolutionise the treatment of autoimmune disease as well as vaccine development. As 'Adaptive Tolerance' demonstrates, autoreactive antibodies are by no means disease drivers which a healthy organism swiftly eliminates. Rather, they trigger the formation of a class of antibodies that protect the body's own structures. https://biopro-v9-test-gi.xanium.io/en/article/press-release/paradigm-shift-immunology-adaptive-tolerance-balances-autoimmune-reaction
Press release - 26/07/2021 Vaccination against hereditary colorectal cancer successful in mice Scientists from the German Cancer Research Center and Heidelberg University Hospital have for the first time been able to delay the development of hereditary colorectal cancer with a protective vaccination. Mice with a hereditary predisposition to colorectal cancer survived significantly longer after vaccination than unvaccinated animals. Combining the vaccination with an anti-inflammatory drug increased the protective effect.https://biopro-v9-test-gi.xanium.io/en/article/press-release/vaccination-against-hereditary-colorectal-cancer-successful-mice
Press release - 13/07/2021 Breakthrough in research on age-related macular degenerationtion Age-related macular degeneration (AMD) is the commonest cause of blindness in developed countries affecting seven million in total in Germany, from which 500,000 people are suffering from late stage disease, around half of whom are registered as visually impaired. There are two forms of AMD, ‘wet’ and ‘dry’. There are currently no treatments available for the dry form of the disease (geographic atrophy).https://biopro-v9-test-gi.xanium.io/en/article/press-release/breakthrough-research-age-related-macular-degenerationtion
Article - 08/07/2021 Individual operation risk assessment by the Cognitive Medical Assistant Despite modern surgical techniques and anaesthetic procedures, serious complications can occur during surgical interventions. An interdisciplinary team at Heidelberg University Hospital has launched a project called the Cognitive Medical Assistant (German: Der Kognitive Medizinische Assistant, KoMed for short), designed to better assess the individual risk of these interventions. The project’s goal is to systematically and comprehensively analyse…https://biopro-v9-test-gi.xanium.io/en/article/news/individual-operation-risk-assessment-cognitive-medical-assistant
Funding Horizone Europe Funding programme, Funded by: European Union, sb_search.searchresult.label.programSubmissionDate: 31/12/2027 https://biopro-v9-test-gi.xanium.io/en/database/funding/horizone-europe
Press release - 10/06/2021 Nose2Brain – Active substances without detour through the nose into the brain Effective drugs for the treatment of diseases of the central nervous system do exist. However, the blood-brain barrier, which protects the brain as the body's control center, makes it especially difficult for therapeutic biomolecules to pass through. Thus, researchers from an international consortium coordinated by the Fraunhofer IGB have spent the last four and a half years developing a novel system in the EU project "N2B-patch"…https://biopro-v9-test-gi.xanium.io/en/article/press-release/nose2brain-active-substances-without-detour-through-nose-brain
Vaccine development - 25/05/2021 Vaccines - a beacon of hope in the fight against pandemics https://biopro-v9-test-gi.xanium.io/en/article/dossier/vaccines-beacon-hope-fight-against-pandemics
Press release - 21/04/2021 Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding Atriva Therapeutics GmbH, a company that is pioneering the development of therapies for the treatment of viral infections, has secured up to €11.4 million in federal funding. The company, founded in 2015, announced today that it was selected for research funding from the German Federal Ministry of Education and Research (BMBF). Atriva will use the funds to advance its drug ATR-002 towards market maturity as quickly as possible.https://biopro-v9-test-gi.xanium.io/en/article/press-release/atriva-therapeutics-kann-dank-foerdermitteln-covid-19-medikament-schneller-entwickeln
Press release - 13/04/2021 Evotec’s BRIDGE “beLAB2122” leverages academic innovation from our region Evotec SE announced today the launch of beLAB2122 in the Rhine- Main-Neckar region to efficiently advance first-in-class therapeutic concepts into investable drug discovery projects. Mediated and supported by BioRN, Evotec’s newest BRIDGE brings together the European Molecular Biology Laboratory (“EMBL”), the German Cancer Research Center (“DKFZ”), the Goethe University Frankfurt, Heidelberg University and the University of Tübingen.https://biopro-v9-test-gi.xanium.io/en/article/press-release/evotecs-bridge-belab2122-leverages-academic-innovation-our-region
Quantum Technology Ulm - 08/04/2021 Diamonds for life sciences innovations The world's first commercial quantum computer,’IBM Q System One’, is now in operation in Ehningen near Stuttgart. This is a major leap forward in quantum technology in Germany. It marks the point at which conventional computers reach their limits. The University of Ulm is involved in three of six collaborative projects being funded by the Baden-Württemberg Ministry of Economic Affairs, Labour and Housing Construction.https://biopro-v9-test-gi.xanium.io/en/article/news/diamonds-life-sciences-innovations
Press release - 03/03/2021 New Baden-Württemberg network to reduce animal experiments A new network has been set up in Baden-Württemberg aimed at reducing animal experiments as well as further improving animal welfare. It combines new approaches and measures at the state’s biomedical research locations, which are expected to limit stress in laboratory animals and steadily reduce the number of animals used in research in line with the 3R principles of Replacement, Reduction, and Refinement.https://biopro-v9-test-gi.xanium.io/en/article/press-release/new-baden-wuerttemberg-network-reduce-animal-experiments
Press release - 28/01/2021 Carl Zeiss Foundation funds Interdisciplinary practice Study at Heidelberg University with the sum of approximately of 4.5 Million Euros Can interconnected digital assistance systems enhance the quality of life of people in older age? Scientists in an interdisciplinary research project at Heidelberg University are exploring this question in a representative practice study. The participating researchers want to investigate how well these technical aids can be used and what benefit they achieve.https://biopro-v9-test-gi.xanium.io/en/article/press-release/carl-zeiss-foundation-funds-interdisciplinary-practice-study-heidelberg-university-sum-approximately-45-million-euros
Lab-on-a-chip - 11/11/2020 Microfluidic platform for the best possible cancer therapy Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.https://biopro-v9-test-gi.xanium.io/en/article/news/microfluidic-platform-best-possible-cancer-therapy
Stem cell therapy for regenerating intervertebral discs - 16/07/2020 Ulm’s simulator has Europe’s back Back pain is often caused by intervertebral disc disorders. Much has already been tried and is available to help patients. Despite extensive progress, there is still no surefire recipe for success. iPSpine, an EU-funded project to which researchers from Ulm are contributing interdisciplinary engineering and biomedical expertise, aims to design a novel therapy for back pain based on intervertebral disc regeneration.https://biopro-v9-test-gi.xanium.io/en/article/news/Ulms-simulator-has-europes-back
Innovations in the field of endoscopy - 08/06/2020 Gastroscopies with pill cameras A pill camera to examine the gastrointestinal tract that can be swallowed without major difficulty, controlled intuitively from the outside and deliver images in real time - why would any doctor or patient say no? To non-experts, it sounds more like science fiction but such a device is actually already in development: since 2019, Tübingen-based Ovesco Endoscopy AG and three partners have been working together on this in a project called nuEndo.https://biopro-v9-test-gi.xanium.io/en/article/news/magenspiegelung-kamerapille